Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CREBBP | Q92793 | 1/20 | 0.36 |
| ▸ | PYGM | P11217 | 1/20 | 0.35 |
| ▸ | IRAK4 | Q9NWZ3 | 2/20 | 0.34 |
| ▸ | IRAK1 | P51617 | 1/20 | 0.34 |
| ▸ | APLNR | P35414 | 1/20 | 0.33 |
| ▸ | PRKCA | P17252 | 3/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL209721 | 1.00 | CREBBP (0.36) | CREBBPPYGMIRAK4IRAK1APLNR | |
| SCHEMBL15549632 | 1.00 | CREBBP (0.36) | CREBBPPYGMIRAK4IRAK1APLNR | |
| SCHEMBL20388887 | 0.84 | IRAK4 (0.33) | PYGMIRAK4IRAK1 | |
| SCHEMBL21338570 | 0.80 | IRAK4 (0.38) | CREBBPPYGMIRAK4APLNRPRKCA | |
| SCHEMBL17137125 | 0.80 | IRAK4 (0.38) | CREBBPPYGMIRAK4APLNRPRKCA | |
| SCHEMBL17136876 | 0.80 | IRAK4 (0.38) | CREBBPPYGMIRAK4APLNRPRKCA | |
| SCHEMBL23724864 | 0.79 | IRAK4 (0.34) | IRAK4IRAK1 | |
| SCHEMBL21241478 | 0.79 | BRD4 (0.36) | CREBBPIRAK4IRAK1 | |
| SCHEMBL21241285 | 0.79 | BRD4 (0.36) | CREBBPIRAK4IRAK1 | |
| SCHEMBL18943857 | 0.79 | BRD4 (0.36) | CREBBPIRAK4IRAK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 88 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12202836-B2 | Bicyclic-fused heteroaryl or aryl compounds | PFIZER INC. (US) | 2025-01-21 | — | — | US | disclosed |
| US-11884624-B2 | Difluorolactam compounds as EP4 receptor-selective agonists for use in the treatment of EP4-mediated diseases and conditions | CAYMAN CHEMICAL COMPANY, INC. (US) | 2024-01-30 | — | — | US | disclosed |
| US-20230339960-A1 | Bicyclic-Fused Heteroaryl or Aryl Compounds | PFIZER (US) | 2023-10-26 | — | — | US | disclosed |
| CN-111971278-B | Quinoline compounds as IRAK inhibitors and uses thereof | 默克专利有限公司 | 2023-08-11 | — | — | CN | disclosed |
| US-11702424-B2 | Bicyclic-fused heteroaryl or aryl compounds | PFIZER INC. (US) | 2023-07-18 | — | — | US | disclosed |
| US-20230050318-A1 | DIFLUOROLACTAM COMPOUNDS AS EP4 RECEPTOR-SELECTIVE AGONISTS FOR USE IN THE TREATMENT OF EP4-MEDIATED DISEASES AND CONDITIONS | CAYMAN CHEMICAL COMPANY, INC. | 2023-02-16 | — | — | US | disclosed |
| US-20230014124-A1 | HETEROCYCLIC DEGRONIMERS FOR TARGET PROTEIN DEGRADATION | C4 THERAPEUTICS, INC. (US) | 2023-01-19 | — | — | US | disclosed |
| US-11345690-B2 | Methods of synthesizing a difluorolactam analog | CAYMAN CHEMICAL COMPANY, INC. (US) | 2022-05-31 | — | — | US | disclosed |
| US-20220127252-A9 | METHODS OF SYNTHESIZING A DIFLUOROLACTAM ANALOG | CAYMAN CHEMICAL CO INC (US) | 2022-04-28 | — | — | US | disclosed |
| EP-3536685-B1 | BICYCLIC-FUSED HETEROARYL OR ARYL COMPOUNDS AND THEIR USE AS IRAK4 INHIBITORS | PFIZER (US) | 2022-02-16 | — | — | EP | disclosed |
| WO-2014015246-A1 | DIFLUOROLACTAM COMPOSITIONS FOR EP4-MEDIATED OSTEO RELATED DISEASES AND CONDITIONS | CAYMAN CHEMICAL COMPANY, INC. (US) | 2014-01-23 | — | — | WO | disclosed |
| WO-2014015246-A1 | DIFLUOROLACTAM COMPOSITIONS FOR EP4-MEDIATED OSTEO RELATED DISEASES AND CONDITIONS | CAYMAN CHEMICAL COMPANY, INC. (US) | 2014-01-23 | — | — | WO | disclosed |
| WO-2014015247-A1 | DIFLUOROLACTAM COMPOUNDS AS EP4 RECEPTOR-SELECTIVE AGONISTS FOR USE IN THE TREATMENT OF EP4-MEDIATED DISEASE AND CONDITIONS | CAYMAN CHEMICAL COMPANY, INC. (US) | 2014-01-23 | — | — | WO | disclosed |
| WO-2014015247-A1 | DIFLUOROLACTAM COMPOUNDS AS EP4 RECEPTOR-SELECTIVE AGONISTS FOR USE IN THE TREATMENT OF EP4-MEDIATED DISEASE AND CONDITIONS | CAYMAN CHEMICAL COMPANY, INC. (US) | 2014-01-23 | — | — | WO | disclosed |
| US-20130053348-A1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS | QIAN XIANGPING (US) | 2013-02-28 | — | — | US | disclosed |
| US-20120135964-A1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS | QIAN XIANGPING (US) | 2012-05-31 | — | — | US | disclosed |
| US-8088793-B2 | Certain chemical entities, compositions, and methods | CYTOKINETICS, INC. (US) | 2012-01-03 | — | — | US | disclosed |
| EP-2195328-A1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS | Cytokinetics, Incorporated (US) | 2010-06-16 | — | — | EP | disclosed |
| US-20090275537-A1 | Certain chemical entities, compositions, and methods | CYTOKINETICS, INC. | 2009-11-05 | — | — | US | disclosed |
| WO-2009023193-A1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS | CYTOKINETICS, INCORPORATED (US) | 2009-02-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230014124-A1 | HETEROCYCLIC DEGRONIMERS FOR TARGET PROTEIN DEGRADATION | CRBN, MDM2, STUB1 | CREBBP 515/4885PYGM 3868/4885IRAK4 4289/4885 |
| US-20090275537-A1 | Certain chemical entities, compositions, and methods | MYLK, MYH2, MYH10 | CREBBP 2318/4885PYGM 15/4885IRAK4 4231/4885 |
| US-20120135964-A1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS | MYLK, MYH2, MYH10 | CREBBP 2318/4885PYGM 15/4885IRAK4 4231/4885 |
| US-20230050318-A1 | DIFLUOROLACTAM COMPOUNDS AS EP4 RECEPTOR-SELECTIVE AGONISTS FOR USE IN THE TREATMENT OF EP4-MEDIATED DISEASES AND CONDITIONS | PTGER4, PTGER1, PTGER3 | CREBBP 1626/4885PYGM 1945/4885IRAK4 535/4885 |
| US-20230339960-A1 | Bicyclic-Fused Heteroaryl or Aryl Compounds | TTR, TYR, ABL1 | CREBBP 1633/4885PYGM 1294/4885IRAK4 1318/4885 |
| US-11884624-B2 | Difluorolactam compounds as EP4 receptor-selective agonists for use in the treatment of EP4-mediated diseases and conditions | PTGER4, PTGER1, PTGER3 | CREBBP 1626/4885PYGM 1945/4885IRAK4 535/4885 |
| US-11345690-B2 | Methods of synthesizing a difluorolactam analog | PTGER4, PTGER1, PTGIR | CREBBP 2311/4885PYGM 1648/4885IRAK4 554/4885 |
| US-12202836-B2 | Bicyclic-fused heteroaryl or aryl compounds | TTR, TYR, ABL1 | CREBBP 1633/4885PYGM 1294/4885IRAK4 1318/4885 |
| US-20130053348-A1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS | MYLK, MYH2, MYH10 | CREBBP 2318/4885PYGM 15/4885IRAK4 4231/4885 |
| US-20220127252-A9 | METHODS OF SYNTHESIZING A DIFLUOROLACTAM ANALOG | PTGER4, PTGER1, PTGIR | CREBBP 2311/4885PYGM 1648/4885IRAK4 554/4885 |
| US-11702424-B2 | Bicyclic-fused heteroaryl or aryl compounds | UGT2B7, CYP3A43, CYP3A4 | CREBBP 3531/4885PYGM 2854/4885IRAK4 4619/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.